RNA interference (RNAi) has emerged as a fundamentally important biological phenomenon and as a versatile, powerful tool for biomedical research. RNAi plays a multifaceted role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and - in its best-studied mode of action - quashing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in many basic research, drug discovery and clinical settings.

In addition to SCIENCE magazine naming RNAi the "breakthrough of the year" (2002) and FORTUNE magazine proclaiming that it is “biotech's billion dollar breakthrough of biotechnology" (2003), its laurels were further enhanced by the awarding of the Nobel Prize for medicine and physiology in 2006 to Andrew Fire and Craig Mello for their work on RNAi, and the well-known series of corporate acquisition and investment by big pharmas like Merck, Novartis and Roche which have injected billions of dollars into this new and promising technology for therapeutics development.

Sirnaomics, Inc. was thus established by a group of leading scientists in this ground-breaking area with the mission of advancing RNAi technology with the proprietary positions on multi-targeted siRNA cocktail design and in vivo siRNA delivery for novel therapeutics. The name of the company Sirnaomics (/ser-'now-miks/) is derived from the tech word "siRNA" with the suffix "-omics" to signify the study of the structure and function of small interfering RNA including their silencing properties and complex interplay with the targeted sequences inside cells.